Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entecavir vs Placebo in Pediatric Chronic Hepatitis B
NCT01079806Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2010
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing Entecavir with Placebo (2 arms). Primary endpoint: Percentage of Participants Who Achieved a Combination of Hepatitis B Virus (HBV) DNA Suppression and Hepatitis B e Antigen (HBeAg) Seroconversion at 48 weeks. Started Jun 2010; status: completed.
02
Drugs
entecavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT01079806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01079806.